Bendamustine versus chlorambucil in treatment of chronic lymphocytic leukaemia in China: a randomized, open-label, parallel-controlled, phase III clinical trial was written by Zhou, Daobin;Xu, Wei;Ma, Hongbing;Zhao, Chunting;Hu, Yu;Zhao, Yaozhong;Wu, Depei;Zhao, Xielan;He, Yanjuan;Yan, Jinsong;Wang, Chunsen;Meng, Fanyi;Jin, Jie;Zhang, Xiaohong;Yu, Kang;Hu, Jianda;Lv, Yue. And the article was included in Investigational New Drugs in 2022.Recommanded Product: 16506-27-7 The following contents are mentioned in the article:
Chronic lymphoblastic leukemia (CLL) is the most common adult leukemia and mainly affects the elderly. Chemoimmunotherapy still has a role in the standard frontline therapy for specific population. However, the clin. activity of bendamustine has not been investigated in unfit Chinese patients with CLL. To compare the efficacy and safety of bendamustine vs. chlorambucil for untreated Chinese patients with Binet stage B/C CLL. Methods. In this multi-center, randomized, open-label, parallel-controlled, phase III trial, patients with previously untreated CLL were enrolled and randomly assigned (1:1) to receive bendamustine or chlorambucil. The primary endpoint was the objective response rate. Secondary endpoints included progression-free survival, the duration of response, and overall survival. Adverse events were recorded to evaluate safety. Of 158 screened patients, 147 were enrolled and randomly allocated to receive bendamustine (n = 72) or chlorambucil (n = 75). After a median follow-up of 25.6 mo (IQR 12.5-27.7), 69.0% (95% CI, 56.9-79.5) of bendamustine-treated patients achieved objective response and 37.0% (95% CI, 26.0-49.1) of chlorambucil with a difference of 32.0% (95%CI: 16.6-47.5), demonstrating the superiority of bendamustine to chlorambucil (p < 0.001). The median progression-free survival was longer for bendamustine (16.5 mo; 95% CI, 11.3-24.7) vs. chlorambucil (9.6 mo; 95% CI, 8.7-11.8; p < 0.001). A longer median duration of response was seen in those receiving bendamustine (19.2 mo; 95% CI, 11.8-29.1) than chlorambucil (10.7 mo; 95% CI, 5.6-13.6; p = 0.0018). Median overall survival was not reached in either group. Overall survival at 18 mo was 88% for bendamustine vs. 85% for chlorambucil. Most common adverse events in both groups were neutropenia and thrombocytopenia. In untreated Chinese patients with Binet stage B/C CLL, bendamustine induced the better objective response and resulted in longer progression-free survival than chlorambucil. Overall, these results validate the role of bendamustine as an effective and safe first-line therapy in this population. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Recommanded Product: 16506-27-7).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Recommanded Product: 16506-27-7
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem